Published in Front Neurol on February 22, 2011
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med (1995) 47.15
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 28.42
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA (1995) 13.37
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 12.92
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet (2007) 10.74
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol (2006) 10.51
Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke (2008) 8.45
The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke (2007) 8.06
The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke (2009) 7.65
NXY-059 for acute ischemic stroke. N Engl J Med (2006) 5.32
Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 5.32
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study. Stroke (2004) 4.67
Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial--Europe Study Group. N Engl J Med (1996) 4.45
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2004) 4.39
Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 4.14
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2008) 3.98
Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol (2009) 3.88
The Interventional Management of Stroke (IMS) II Study. Stroke (2007) 3.83
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA (2000) 3.75
Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology (1992) 3.40
The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology (1999) 3.03
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke (2006) 3.03
Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol (1993) 2.91
Methodology of the Interventional Management of Stroke III Trial. Int J Stroke (2008) 2.88
Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke (1999) 2.85
Mechanical thrombectomy with the Solitaire AB device in large artery occlusions of the anterior circulation: a pilot study. Stroke (2010) 2.78
MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke (2004) 2.75
Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA (1996) 2.67
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol (2004) 2.65
Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2003) 2.21
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology (2002) 2.18
Efficacy of intra-arterial fibrinolysis for acute ischemic stroke: meta-analysis of randomized controlled trials. Stroke (2010) 2.17
The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol (2008) 2.08
Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol (1996) 2.05
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke (2006) 1.99
Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke (2002) 1.85
A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke (2005) 1.83
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke (2008) 1.79
Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II). Stroke (2010) 1.72
Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke (2006) 1.70
Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study. Stroke (2000) 1.60
Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke (2000) 1.58
Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials. AJNR Am J Neuroradiol (2009) 1.51
Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology (1992) 1.51
Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke (2007) 1.45
Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke (2005) 1.28
Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol (2003) 1.27
Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke (2010) 1.22
Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke (2000) 1.22
Mechanical thrombectomy for acute ischemic stroke: thrombus-device interaction, efficiency, and complications in vivo. Stroke (2006) 1.16
Intravenous alteplase for ischaemic stroke. Lancet (2007) 1.14
Combined intraarterial/intravenous thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol (2001) 1.14
Intravenous glycoprotein IIb/IIIa inhibitor (tirofiban) followed by intra-arterial urokinase and mechanical thrombolysis in stroke. AJNR Am J Neuroradiol (2005) 1.03
A novel microcatheter-delivered, highly-flexible and fully-retrievable stent, specifically designed for intracranial use. Technical note. Interv Neuroradiol (2004) 1.03
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am J Neuroradiol (2004) 1.03
Existence of the diffusion-perfusion mismatch within 24 hours after onset of acute stroke: dependence on proximal arterial occlusion. Radiology (2009) 1.01
Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke. J Cereb Blood Flow Metab (1998) 0.97
Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke (2009) 0.96
Use of the New Solitaire (TM) AB Device for Mechanical Thrombectomy when Merci Clot Retriever Has Failed to Remove the Clot. A Case Report. Interv Neuroradiol (2009) 0.93
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation (2000) 0.87
Vertebrobasilar thrombolysis with intravenous tirofiban: case report. J Thromb Thrombolysis (2002) 0.87
Comparison of mechanical embolectomy and intraarterial thrombolysis in acute ischemic stroke within the MCA: MERCI and Multi MERCI compared to PROACT II. Neurocrit Care (2008) 0.81
Safety of eptifibatide for subcortical stroke progression. Cerebrovasc Dis (2009) 0.79
[Endovascular treatment for acute stroke: an open field to begin]. Neurologia (2010) 0.76
Clinical applicability and the perfusion-diffusion mismatch theory: not yet a perfect match. Neurology (2010) 0.76
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
The pathogenetic significance of intestinal Candida colonization--a systematic review from an interdisciplinary and environmental medical point of view. Int J Hyg Environ Health (2002) 1.50
Molecular junctions based on aromatic coupling. Nat Nanotechnol (2008) 1.48
Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner. J Immunol (2008) 1.36
Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke (2013) 1.25
Lifestyle risk factors for ischemic stroke and transient ischemic attack in young adults in the Stroke in Young Fabry Patients study. Stroke (2012) 1.14
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol (2006) 1.07
Electrical conductance of molecular junctions by a robust statistical analysis. Nano Lett (2006) 1.02
Body fat distribution as a risk factor for cerebrovascular disease: an MRI-based body fat quantification study. Cerebrovasc Dis (2013) 0.94
Do plant cyclotides have potential as immunosuppressant peptides? J Nat Prod (2012) 0.94
Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med (2012) 0.89
Valvular strands and ischemic stroke. Eur Neurol (2007) 0.88
Cyclotides Suppress Human T-Lymphocyte Proliferation by an Interleukin 2-Dependent Mechanism. PLoS One (2013) 0.87
Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment. Learn Mem (2006) 0.85
Electrical conductance of atomic contacts in liquid environments. Small (2005) 0.84
Atypical botulism sparing palsy of extraocular muscles. Eur J Med Res (2007) 0.83
Screening for cognitive impairment in patients with acute stroke. Dement Geriatr Cogn Disord (2003) 0.83
Connective tissue disorders in dissections of the carotid or vertebral arteries. J Clin Neurosci (2008) 0.83
Long-term mortality and risk of stroke after transient ischemic attack: a hospital-based cohort study. J Neurol (2009) 0.82
Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol (2012) 0.82
Immunomodulatory properties of a lemon-quince preparation (Gencydo®) as an indicator of anti-allergic potency. Phytomedicine (2011) 0.81
Trans-synaptic increase of hypoxic tolerance in hippocampus upon physical challenge with two-photon microscopy. Hippocampus (2002) 0.80
Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem Res (2007) 0.80
A biochemical marker panel in MRI-proven hyperacute ischemic stroke-a prospective study. BMC Neurol (2012) 0.79
Equisetum arvense (common horsetail) modulates the function of inflammatory immunocompetent cells. BMC Complement Altern Med (2014) 0.79
New cruciform structures: toward coordination induced single molecule switches. J Org Chem (2007) 0.79
In vitro cytotoxicity of cyclodextrin-bonded birch bark extract. Planta Med (2012) 0.78
Overexpression of manganese superoxide dismutase in human dermal fibroblasts enhances the contraction of free floating collagen lattice: implications for ageing and hyperplastic scar formation. Arch Dermatol Res (2009) 0.78
Preclinical evaluation of 4-methylthiobutyl isothiocyanate on liver cancer and cancer stem cells with different p53 status. PLoS One (2013) 0.78
An aqueous birch leaf extract of Betula pendula inhibits the growth and cell division of inflammatory lymphocytes. J Ethnopharmacol (2011) 0.78
Bicycle helmet ventilation and comfort angle dependence. Eur J Appl Physiol (2004) 0.77
Enhanced in vitro activation of immunocompetent cells in healthy individuals being subcutaneously 'vaccinated' with placebo (physiological saline). Clin Immunol (2008) 0.77
MRI-based separation of congenital and acquired vertebrobasilar artery anomalies in ischemic stroke of the posterior circulation. Stroke (2008) 0.77
Traditionally used Veronica officinalis inhibits proinflammatory mediators via the NF-κB signalling pathway in a human lung cell line. J Ethnopharmacol (2012) 0.77
Clinically relevant depressive symptoms in young stroke patients - results of the sifap1 study. Neuroepidemiology (2015) 0.77
Inhibition of corneal inflammation following keratoplasty by birch leaf extract. Exp Eye Res (2012) 0.77
Long-term outcome in transient global amnesia patients with and without focal hyperintensities in the CA1 region of the hippocampus. Eur Neurol (2012) 0.76
[Quality and safety of Chinese medicine drugs in Germany - an update]. Forsch Komplementmed (2014) 0.75
Cervical artery dissection in young adults in the stroke in young Fabry patients (sifap1) study. Cerebrovasc Dis (2015) 0.75
Secondary stroke prevention: inside the vessels and beyond. CNS Drugs (2008) 0.75
Pomegranate (Punica granatum) Seed Oil for Treating Menopausal Symptoms: An Individually Controlled Cohort Study. Altern Ther Health Med (2017) 0.75
Novel cruciform structures as model compounds for coordination induced single molecule switches. Chimia (Aarau) (2010) 0.75
Effects of Sulfate-Rich Mineral Water on Functional Constipation: A Double-Blind, Randomized, Placebo-Controlled Study. Forsch Komplementmed (2016) 0.75
The stamp of ancestry: roots of behavioral and neuronal impairment in adulthood. Exp Neurol (2006) 0.75